REGENLAB
12.6.2024 15:01:28 CEST | Business Wire | Press release
RegenLab, a pioneering biotechnology company specializing in the research, development, and manufacturing of patented cell and tissue engineering medical devices, has been honored with the “Innovation Champion Award” by the European Investment Bank (EIB) at the European Convention Center in Luxembourg.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611846846/en/
RegenLab France receives prestigious EU-EIB Innovation Champion Award. Antoine Turzi, CEO and Founder of RegenLab, pictured between two officials of the European Investment Bank. (Photo: Business Wire)
This prestigious award recognizes RegenLab France’s commitment to “reshoring” by establishing a state-of-the-art biotechnology factory in Paris-Saclay and its innovation, the REGENMATRIX® PRP-HA. This next-generation product combines Platelet-Rich Plasma (PRP) with cross-linked Hyaluronic Acid (HA) in a single tube, designed specifically to address the needs of patients with advanced grade III-IV knee osteoarthritis. Currently, a clinical study is underway in 16 university hospitals across France to demonstrate the effectiveness and safety of this groundbreaking treatment.
“We are honored and delighted to receive this award from the European Investment Bank,” said Mr. Antoine Turzi, Founder & CEO of RegenLab France. “This recognition celebrates the successful completion of our French factory and our ongoing R&D efforts. Our goal is to innovate in cell therapies and enhance the well-being of patients, while supporting industry reshoring in France.”
RegenLab’s achievement not only highlights its dedication to advancing medical science but also underscores the pivotal role of the EIB in promoting innovation, its sustainable growth across Europe and its competitiveness worldwide.
Based in Paris Saclay, RegenLab France is a company specialized in the R&D and manufacturing of tissue engineering medical devices supported by 100 patents. The Company’s solutions are commercialized in more than 90 countries. The core technology of the Company is manufacturing of medical devices for autologous platelet-rich plasma (PRP) & Tissue Engineering, consisting in reinjecting the patient’s own cells and platelets into tissue lesions in order to stimulate tissue healing. The RegenKit, CellularMatrix… brands, have been CE marked EU-MDR 2017/745 and approved by US-FDA, CFDA & worldwide regulatory agencies; they are routinely used for the treatment of a wide variety of indications including joint osteoarthritis, tendinopathies, woman health and dermo-aesthetics. The Company’s medical devices are also manufactured in the factory of Le Mont-sur-Lausanne (Switzerland) & New York (USA).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611846846/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Visa Introduces Platform for Stablecoin Minting, Movement and Management16.7.2026 16:30:00 CEST | Press release
The Visa Stablecoin Platform gives financial institutions, fintechs and other payment providers a single environment to come onchain and run stablecoin operations with Visa. Today, Visa (NYSE: V) announced the Visa Stablecoin Platform (VSP), a new enterprise platform designed to help financial institutions, fintechs, and crypto natives access stablecoin capabilities through a single Visa-managed environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716292689/en/ Building on Visa’s broader crypto strategy, VSP gives FIs, fintechs and other payment providers a simple way to access, store, and redeem stablecoins, beginning with Open USD (OUSD), a new stablecoin recently introduced by Open Standard. This includes onchain wallet infrastructure through a newly introduced Wallet-as-a-Service offering and connectivity for minting and burning Open USD. “Stablecoins are opening up a new layer of programmable money, but for mo
Cyclic Materials Appoints Tomasz Poznar as Chief Commercial Officer to Accelerate Global Commercial Growth16.7.2026 15:20:00 CEST | Press release
Industry leader in critical materials and battery recycling to drive Cyclic’s global commercial growth and strategic partnerships. Cyclic Materials, the rare earth recycling company building a circular supply chain for rare earth elements and critical materials, today announced the appointment of Tomasz Poznar, Ph.D., as Chief Commercial Officer. The appointment strengthens Cyclic Materials’ executive team as the company accelerates commercial expansion across North America, Europe, and Asia. Most recently, Poznar served as Chief Commercial Officer at Ascend Elements, where he led the company’s global commercial strategy, strategic partnerships, and business development. During his tenure, he helped secure more than USD $1.5 billion in commercial agreements, including a landmark USD $1 billion supply agreement with a major global automaker, while also supporting approximately USD $320 million in TCTF government funding that accelerated the company’s growth in North America and Europe.
Modon Holding and Nammos Hotels & Resorts Bring Nammos Ras El Hekma to Egypt’s North Coast16.7.2026 14:50:00 CEST | Press release
Developed in partnership with Nammos Hotels & Resorts, the landmark Mediterranean destination will bring together branded residences, a luxury resort, restaurant and beach club, retail village, and signature dining and wellness experiences to Egypt for the first time. Abu Dhabi-based Modon Holding and Nammos Hotels & Resorts have announced Nammos Ras El Hekma – the renowned lifestyle and hospitality brand’s first fully integrated destination in Egypt. Located within the Wadi Yemm precinct, the development will bring Ras El Hekma’s promise of timeless Mediterranean living to life, combining Nammos Residences, Nammos Resort, Nammos Village, and a curated selection of all-day dining and wellness experiences, including the globally renowned Nammos Restaurant & Beach Club. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716740934/en/ Modon Holding and Nammos Hotels & Resorts bring Nammos Ras El Hekma to Egypt’s North Coast (Pho
Tridiagonal.ai (T.AI) Partners with PETRONAS Carigali’s TriCipta AI with IBM to Advance Engineering Domain-Driven AI Solutions for Upstream Operations16.7.2026 14:30:00 CEST | Press release
Tridiagonal.ai will contribute engineering domain-driven AI solutions, physics-informed models and Decision Intelligence capabilities to support upstream surface equipment optimisation, maintenance reliability and asset integrity decision workflows. Tridiagonal.ai Pvt. Ltd. (T.AI), the dedicated AI arm of Tridiagonal Group, announced its role in the third Joint Development Agreement (JDA) involving PETRONAS Carigali Sdn. Bhd. and IBM Malaysia Sdn. Bhd. to advance PETRONAS Carigali’s flagship TriCipta AI across the Upstream value chain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260715579933/en/ Signing ceremony for the third TriCipta AI Joint Development Agreement, attended by executives from Tridiagonal.ai (T.AI), PETRONAS Carigali, and IBM Malaysia. TriCipta AI is PETRONAS Carigali’s partnership model that combines deep domain technical expertise with advanced AI technology experts to accelerate the development and dep
Crown Bioscience Joins C-Path's NAMs Developer Coalition to Advance Human-Relevant Models in Drug Development16.7.2026 14:30:00 CEST | Press release
Global CRO brings patient-derived models, organoid platforms and biomarker expertise to collaborative effort advancing regulatory acceptance of New Approach Methodologies Crown Bioscience is a global contract research organization (CRO) specializing in oncology drug discovery and development, today announced it has joined Critical Path Institute's (C-Path) New Approach Methodologies Developer Coalition (NAMs-DC), a collaborative initiative dedicated to advancing the validation, qualification and regulatory adoption of innovative human-relevant research methods. Crown Bioscience joins a growing community of technology developers, pharmaceutical companies, regulatory stakeholders and scientific experts working to accelerate the adoption of New Approach Methodologies (NAMs) across drug discovery and development. Through its participation in NAMs-DC, Crown Bioscience will contribute expertise spanning patient-derived xenograft (PDX) models, patient-derived tumor organoids, ex vivo patient
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom